Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:46:26 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CPRX - CATALYST PHARMACEUTICALS INC - http://www.copper-ridge.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPRX - Q0.114.81·15.180.114.89+0.211.4772.511,1165,35514.84  15.06  14.70517.765  11.0919:24:31Apr 2215 min RT 2¢

Recent Trades - Last 10 of 5355
Time ETExPriceChangeVolume
19:24:31Q15.190.5170
19:21:19Q15.190.511
19:14:05Q14.820.1412
19:04:59Q14.820.1420
19:01:42Q14.810.131
18:55:47Q14.810.131
18:55:03Q14.810.131
18:53:59Q14.810.1325
18:46:49Q14.810.131
18:46:24Q14.810.1386

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-22 08:00U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
2024-03-28 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
2024-03-27 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
2024-03-13 07:55U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces AGAMREE(TM) Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
2024-03-05 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
2024-02-28 18:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-27 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
2024-02-21 09:00U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical ¢ € ™s VISION-DMD Vamorolone (AGAMREE ‚ ®) Study Results in the Peer-Reviewed Journal Neurology
2024-02-14 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-09 16:05U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
2024-01-05 08:02U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
2024-01-04 16:50U:CPRXNews ReleaseCatalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2023-12-18 06:30U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces FIRDAPSE ‚ ® New Drug Application Submitted in Japan by Partner DyDo Pharma
2023-12-05 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
2023-12-04 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
2023-11-16 08:05U:CPRXNews ReleaseCatalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
2023-11-08 16:11U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
2023-11-02 10:38U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE ‚ ®
2023-10-30 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
2023-10-26 15:19U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports FDA Approval of AGAMREE ‚ ® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals